487 6. Complicanze tardive Bibliografia [1] Lee SJ, Vogelsang G, Flowers MED. Chronic graft versus host disease. Biol Blood Marrow Transplant. 2003;9(4):215–233. [2] Lee SJ, Flowers ME. Recognizing and managing chronic graft versus host disease. Hematology Am Soc Hematol Educ Program. 2008;2008:134–141. [3] Ferrara JLM, Levine J, Reddy P, Holler E. Graft versus host disease. Lancet. 2009;373(9674):1550–1561. [4] Lee SJ. Classification systems for chronic graft versus host disease. Blood. 2017;129(1):30–37. [5] Schoemans HM, Lee SJ, Ferrara JL, et al. EBMT Transplant Complications Working Party and the “EBMT−NIH CIBMTR Task Force”. EBMT NIH CIBMTR Task Force position statement on standardized terminology & guidance for graft versus host disease assessment. Bone Marrow Transplant. 2018;53(11):1401–1415. [6] Arai S, Arora M, Wang T, et al. Graft vs Host Disease Working Committee of the CIBMTR. Increasing incidence of chronic graft ver sus host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant. 2015 Feb;21(2):266–274. [7] Jagasia M, Giglia J, Chinratanalab W et al. Incidence and outcome of chronic graft versus host disease using National Institutes of Health con sensus criteria. Biol Blood Marrow Transplant. 2007;13(10):1207–1215. [8] Grube M, Holler E, Weber D, et al. Risk factors and outcome of chronic graft versus host disease after allogeneic stem cell transplantation: Results from a single center observational study. Biol Blood Marrow Transplant. 2016;22(10):1781–1791. [9] Lazaryan A, Weisdorf DJ, DeFor T, et al. Risk factors for acute and chronic graft versus host disease after allogeneic hematopoietic cell transplantation with umbilical cord blood and matched related donors. Biol Blood Marrow Transplant. 2016;22(1):134–140. [10] Arora M, Pidala J, Cutler CS, et al. Impact of prior acute GVHD on chronic GVHD outcomes: a chronic graft versus host disease consortium study. Leukemia. 2013;27(5):1196–1201. [11] MacDonald KP, Hill GR, Blazar BR. Chronic graft versus host disease: biological insights from preclinical and clinical studies. Blood. 2017;129(1):13–21. [12] Socie G, Peffault de Latour R, Bouziz JD, Rybojad M. Acute and chronic skin graft versus host disease pathophysiological aspects. Curr Probl Dermatol. 2012;43:91–100. [13] Blazar BR, Murphy WJ, Abedi M. Advances in graft versus host disease biology and therapy. Nat Rev Immunol. 2012;12(6):443– 458. [14] Socie G, Ritz J. Current issues in chronic graft versus host disease. Blood. 2014;124(3):374–384. [15] Cooke KR, Luznik L, Sarantopoulos S, et al. The Biology of Chronic Graft versus Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft versus Host Disease. Biol Blood Marrow Transplant. 2017;23(2):211–234. [16] Heidegger S, van den Brink MR, Haas T, Poeck H. The role of pattern recognition receptors in graft versus host disease and graft versus leukemia after allogeneic stem cell transplantation. Front Immunol. 2014;5:337. [17] Wilson NJ, Boniface K, Chan JR, et al. Development, cytokine profile and function of human interleukin 17 producing helper T cells. Nat Immunol. 2007;8(9):950–957. [18] Sarantopoulos S, Ritz J. Aberrant B cell homeostasis in chronic GVHD. Blood. 2015;125(11):1703–1707. [19] Li X, Gao Q, Feng Y, Zhang X. Developing role of B cells in the pathogenesis and treatment of chronic GVHD. Br J Haematol. 2019;184(3):323–336. [20] Greinix HT, Kuzmina Z, Weigl R, et al. CD19+CD21low B cells and CD4+CD45RA+CD31+ T cells correlate with first diagnosis of chronic graft versus host disease. Biol Blood Marrow Transplant. 2015;21(2): 250–258. [21] Khoder A, Sarvaria A, Alsuliman A, et al. Regulatory B cells are enriched within the IgM memory and transitional subsets in healthy donors but are deficient in chronic GVHD. Blood. 2014;124(13):2034–2045. [22] Ukena SN, Velaga S, Geffers R, et al. Human regulatory T cells in allogeneic stem cell transplantation. Blood. 2011;118(13):e82– 92. [23] Schultz K. Pathophysiology of chronic graft-versus-host disease. In: Vogelsang G, Pavletic S, editors. Chronic Graft Versus Host Disease: Interdisciplinary Management. Cambridge: Cambridge University Press; 2009. p. 17–30. [24] Bruggen MC, Klein I, Greinix H, et al. Diverse T-cell responses characterize the different manifestations of cutaneous graftversus-host disease. Blood 2014;123:290–9. [25] Okiyama N, Furumoto Y, Villarroel VA, et al. Reversal of CD8 T-cell-mediated mucocutaneous graft-versus-host-like disease by the JAK inhibitor tofacitinib. J Invest Dermatol 2014;134:992– 1000. [26] Alexander KA, Flynn R, Lineburg KE, et al. CSF-1- dependant donor-derived macrophages mediate chronic graft-versus-host disease. J Clin Invest 2014;124:4266–80. [27] Ochs LA, Blazar BR, Roy J, et al. Cytokine expression in human cutaneous chronic graft-versus-host disease. Bone Marrow Transplant. 1996;17:1 085-1092 [28] Svegliati S, Olivieri A, Campelli N, et al. Stimulatory autoantibodies to PDGF receptor in patients with extensive chronic graft-versus-host disease. Blood. 2007;110:237-241. [29] Zhang Y, McCormick LL, Desai SR, et al. Murine sclerodermatous graft-versus-host disease, a model for human scleroderma: cutaneous cytokines, che- mokines, and immune cell activation. J Immunol. 2002;168:3088-3098. [30] Hillen U, Hausermann P, Massi D, et al. Consensus on performing skin biopsies, laboratory workup, evaluation of tissue samples and reporting of the results in patients with suspected cutaneous graft versus host disease. J Eur Acad Dermatol Venereol. 2014;29(5):948–954. [31] Lerner KG, Kao GF, Storb R, et al. Histopathology of graft vs. host reaction (GvHR) in human recipients of marrow from HL A matched sibling donors. Transplant Proc. 1974;6:367–371. [32] Ziemer M, Haeusermann P, Janin A, et al. Histopathological diagnosis of graft versus host disease of the skin: an interobserver comparison. J Eur Acad Dermatol Venereol. 2014;28:915–924. [33] Hymes SR, Turner ML, Champlin RE, et al. Cutaneous manifestations of chronic graft versus host disease. Biol Blood Marrow Transplant. 2006;12:1101–1113. [34] Janin A, Socie G, Devergie A, et al. Fasciitis in chronic graft versus host disease. A clinicopathologic study of 14 cases. Ann Intern Med. 1994;120:993–998. [35] White JM, Devereux S, Pagliuca A, et al. Koebnerizing sclerodermatous graft versus host disease caused by donor lymphocyte infusion and interferon alpha. Br J Dermatol. 2006;155:621–623. [36] Strong Rodrigues K, Oliveira Ribeiro C, de Abreu Fiuza Gomes S, et al. Cutaneous Graft Versus Host Disease: Diagnosis and Treatment. Am J Clin Dermatol. 2018;19(1):33–50.
RkJQdWJsaXNoZXIy ODUzNzk5